To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.

You can also follow us on one of these media :

The European AIDS Treatment Group is a voluntary membership based patient organization. Your donation will help us produce and distribute more HIV treatment information, reach out to communities to provide trainings and continue to advocate at the European level on treatment-related issues of concern to our membership.

Biomarkers of inflammation increase during acute HIV infection and remain elevated despite early suppressive antiretroviral therapy, according to a study presented at CROI 2015, in Seattle, Washington.
The study, presented by Netanya Sandler Utay, M.D., followed 78 acutely HIV-infected individuals and 109 HIV-negative individuals from Thailand, from diagnosis or enrollment to 96...

LPV, ATV, NVP, but not EFV, tied to higher non-AIDS death rate in D:A:D
Analysis of the D:A:D cohort linked cumulative use of lopinavir, atazanavir, or nevirapine to small but significant increases in the non-AIDS death rate [1]. The same analysis tied recent efavirenz exposure to about a 15% lower non-AIDS death rate.
D:A:D is the large ongoing study of...

Natco Pharma Ltd said on Monday it has agreed a deal with Gilead Sciences Inc to supply generic copies of the U.S. drugmaker's chronic hepatitis C medicines, including $1,000-a-pill drug Sovaldi, in 91 developing nations.
Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having...

EHRIN is a new pan-European health research network designed to facilitate links and funding opportunities between small and medium-sized enterprises, academia, and allied organisations in the life sciences sector.
EHRIN, a new pan-European health research network designed to facilitate links and funding opportunities between small and medium-sized enterprises, academia, and allied...

Long-term antiretroviral treatment of HIV does not protect against anal cancer.
Long-term antiretroviral (ARV) treatment of HIV does not protect against anal cancer, according to a French study. This is a concern because rates of anal cancer are markedly high among people living with HIV, in particular men who have sex with men (MSM). Published in the Journal of Clinical Oncology and first...

Researchers who aim to assess adherence to HIV or HCV therapy need to take financial stress into account in future studies, particularly when such studies are done in high-income countries.
Adherence—taking medicines exactly as prescribed—is critical to the success of medications and treating illness, particularly infections. In order for potent combination anti-HIV therapy (commonly...

Neurocognitive impairment in people with HIV is most likely to be happening for the same reasons as in the wider population, and the risk of impairment does not appear to be associated with HIV infection.
Neurocognitive impairment in people with HIV - loss of memory, poor concentration and declining mental ability - is most likely to be happening for the same reasons as in the wider...

The data underscore the need for further research into potential mechanisms by which ART may affect birth outcomes as well as investigation of the safest antiretroviral regimens for use during pregnancy.
Among HIV-infected women in Botswana starting combination antiretroviral therapy during pregnancy was associated with an increased risk for adverse birth outcomes including preterm...

Biomarkers of inflammation increase during acute HIV infection and remain elevated despite early suppressive antiretroviral therapy, according to a study presented at CROI 2015, in Seattle, Washington.
The study, presented by Netanya Sandler Utay, M.D., followed 78 acutely HIV-infected individuals and 109 HIV-negative individuals from Thailand, from diagnosis or enrollment to 96...

LPV, ATV, NVP, but not EFV, tied to higher non-AIDS death rate in D:A:D
Analysis of the D:A:D cohort linked cumulative use of lopinavir, atazanavir, or nevirapine to small but significant increases in the non-AIDS death rate [1]. The same analysis tied recent efavirenz exposure to about a 15% lower non-AIDS death rate.
D:A:D is the large ongoing study of...

Natco Pharma Ltd said on Monday it has agreed a deal with Gilead Sciences Inc to supply generic copies of the U.S. drugmaker's chronic hepatitis C medicines, including $1,000-a-pill drug Sovaldi, in 91 developing nations.
Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having...

MILFORD, Mass., February 26, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of Hepatitis B virus (HBV) and other viral infections, today announced the closing of a $22 million financing. Funds from this financing will accelerate the advancement of SB 9200, a novel, broad spectrum antiviral agent...

NIH-supported researchers find latency gives virus survival advantage
​ WHAT:
A major hurdle to curing people of HIV infection is the way the virus hides in a reservoir composed primarily of dormant immune cells. It is generally believed that HIV does not replicate in these cells because the virus depends on active cellular machinery to do so. Now, two new papers by...

A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class, researchers reported yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) , taking place this week in Seattle, USA.
Combination...

ABIVAX recruits first patient in a pivotal Phase IIb/III clinical trial with ABX203, a novel immunotherapy against chronic hepatitis B

Paris, February 26, 2015 – ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. The study is designed to assess whether ABX203 can deliver a...

CAPE TOWN – South Africa’s new policy on patents could go to the Cabinet for approval soon, says Doctors without Borders (Médecins Sans Frontières, MSF), one of the organisations spearheading the Fix the Patent Laws campaign in the country.
The draft intellectual property policy has been circulated for comments since its release in September 2013....

EHRN addressed a letter to SIIC, whereby it strongly recommends considering the need to hold a Partnership Forum in EECA for the region to engage with the development of the Global Fund Strategy 2017-2021
In 2015, the process to develop the Global Fund 2017-2021 Strategy is about to begin. The Global Fund is governed by a broad range of groups: from...

Romania’s Ministry of Health approves the country’s National Strategy for TB Control 2015-2020

26 February 2015 - Romania - The Romanian government this week approved the National Strategy for TB Control for the period 2015-2020. The Strategy aims to reduce TB incidence and mortality by providing prevention, screening, diagnosis, treatment and an increased adherence to treatment as recommended by WHO. Despite progress in the last 12 years, Romania still has one of the highest...

Why the request by least developed countries for an extension of the transitional period for granting and enforcing medicines patents needs to be supported

On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request for an extension of the transitional period under article 66.1 TRIPS with respect to pharmaceutical products until the country is no longer classified as LDC.[1] The original extension, set to expire on 1 st January 2016, specifically removes...

Global health partners begin building a new approach to ensure equitable access to medicines

Global health partners met in Geneva to begin the process of building a new approach to better determine health needs and constraints and addressing them in countries.
The new framework, the Equitable Access Initiative, aims to better inform international decision making processes on health and development, particularly where they rely on traditional gross-national-income...

The European AIDS Treatment Group and AVAC organized an unprecedented three-day workshop: New Developments in HIV Prevention . The EATG-AVAC collaboration is an attempt to update EATG members on the latest developments in biomedical HIV prevention approaches; facilitate the exchange of state-of-the-art information on HIV prevention research topics between researchers...

The European AIDS Treatment Group and AVAC organized an unprecedented three-day workshop: New Developments in HIV Prevention . The EATG-AVAC collaboration is an attempt to update EATG members on the latest developments in biomedical HIV prevention approaches; facilitate the exchange of state-of-the-art information on HIV prevention research topics between researchers...

Experts from WHO/Europe and the European AIDS Treatment Group will answer your questions on the strategic use of antiretrovirals, including to prevent HIV infections, during a live Twitter chat on Wednesday 19 December 2012, at 14:00–15:00 UTC/GMT (15:00–16:00 CET, Copenhagen time).
The chat will be hosted by Irina Eramova and Smiljka de Lussigny from the HIV/AIDS, STIs...

Presenting the new and improved TBOnline.info – your source for TB news!

We are pleased to announce the completed renovation of TB Online – a website for activists, patients, healthcare workers, and researchers to learn more about tuberculosis (TB).
The website is maintained with the support of the European AIDS Treatment Group (EATG) and Treatment Action Group (TAG).
TB Online is the official site of the Global TB Community Advisory Board...

Europe needs the HIV prevention pill now
Pre-exposure prophylaxis could slash HIV infections in our most vulnerable communities
Seattle, Tuesday 24 February 2015: The European AIDS Treatment Group (EATG), Europe’s network of HIV activists and AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV, LGBT civil society...

Civil society call to the EU trio Presidencies to follow up on discussed ministerial declaration on HIV and co-infection in Europe and Central Asia

On 16 February, the EU HIV Civil Society Forum wrote to the trio EU Presidency to follow up on the conclusions of the EU Italian High Level Presidency recommending further work on a ministerial Declaration on HIV/AIDS and co-infections in Europe and Central Asia .
Brussels, 16 February 2015
We are writing on behalf of the EU HIV Civil Society Forum on HIV to follow up on the...

Report from November 2014 EU HIV Civil Society Forum and presentations published

The EU HIV Civil Society Forum on HIV has just published the report and supporting documents of its November 2014 meeting.
The meeting addressed the following items: the EU Presidency ministerial conference on HIV and declaration; the ECDC report of progress made on the last ten years and challenges ahead; the continued need for a new policy framework on HIV, TB, Hepatitis C and STIs...

The European AIDS Treatment Group and AVAC organized an unprecedented three-day workshop: New Developments in HIV Prevention . The EATG-AVAC collaboration is an attempt to update EATG members on the latest developments in biomedical HIV prevention approaches; facilitate the exchange of state-of-the-art information on HIV prevention research topics between researchers...

During 16-18 November 2012 the European AIDS Treatment Group is organizing a training on HIV/AIDS Treatment Literacy and Treatment Advocacy in Almaty, Kazakhstan. The training is specifically tailored for the cohort of young professionals from Eastern Europe and Central Asia countries, taking into consideration region-specific issues, including fewer resources, greater stigma, weaker...

EATG General Assembly 2012 - election of new board members and working group chairs

EATG is pleased to introduce its new board of directors and Working Group chairs
During the 2012 EATG General Assembly a new board was chosen within the organisation . Brian West, UK and already board member since 1 year will be the chair of the EATG Tomislav Vurusic, Croatia is the treasurer Tamás Bereczky, Hungary is the new secretary Ferenc Bagyinszky, Hungary is vice-chair...

EATG is proud and honored to have received a Red Award for the work that has been done in the past 20 years on HIV, treatment and access at the Reminders Night event in Berlin on September 22.
On Saturday night September 22 the members and staff of EATG were honored by receiving the Red Award for the 20 years of work that the organization has been doing on HIV treatment access and...

Europe needs the HIV prevention pill now
Pre-exposure prophylaxis could slash HIV infections in our most vulnerable communities
Seattle, Tuesday 24 February 2015: The European AIDS Treatment Group (EATG), Europe’s network of HIV activists and AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV, LGBT civil society...

The seventh international workshop on viral hepatitis, held in Sitges, Barcelona, Spain - aka “Sitges VII” focused on access to treatment and care for people living with hepatitis C, whether living with hepatitis C alone or living with HIV co-infection. Community delegates and their allies met with representatives of pharmaceutical industry between Friday 3rd through Sunday 5th of...

The following activities have been planned for the year 2015 for the European Community Advisory Board:
January 23-25 EATG/AVAC Meeting on Prevention –Brussels(Belgium)
March 20-22 ECAB HIV –Brussels(Belgium)
May 22-24 ECAB HCV – Budapest (Hungary)
June 19-21 ECAB HIV - Bucharest (Romania)...

Expanded access, compassionate use programmes & affordable pricing for Sovaldi & new HCV drugs: urgently needed by people living with hepatitis C

Official European AIDS Treatment Group (EATG) Press Statement released at the European Community Advisory Board Thematic Hepatitis C Meeting: Lisbon, Portugal
Pharmaceutical companies must provide access to their game-changing oral hepatitis C drugs to people with hepatitis C virus (HCV) who need them most, through life-saving...

Europe needs the HIV prevention pill now
Pre-exposure prophylaxis could slash HIV infections in our most vulnerable communities
Seattle, Tuesday 24 February 2015: The European AIDS Treatment Group (EATG), Europe’s network of HIV activists and AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV, LGBT civil society...

The British HIV Association (BHIVA) will hold the annual HIV/Hepatitis Co-infection Conference the 8-9 December London. This annual conference brings together those directly involved in the care of HIV-infected patients co-infected with hepatitis B or C, as well as those who have a clinical or research interest in the epidemiology, natural history or basic science of viral hepatitis....

New learning/teaching methodologies tailored towards patients at large

EUPATI work package 7 is initiating its work on deliverable D7.4 (see subject line). It is our goal to identify new teaching methodologies and to provide guidance on the use of media, information technology and teaching material to non-expert patients and the public at large. D7.4 output is not designed to inform the ongoing EUPATI project itself but should inform sustainability planning...

This is an announcement for the Correlation Hepatitis C and Drug Use Conference 23 - 24.10. 2014 in Berlin.
The conference will bring together key actors on HCV, including drug user community representatives, harm reduction experts, health care professionals, pharmaceutical companies, researchers and policy makers to develop pathways for effective health responses and to open...

Europe needs the HIV prevention pill now
Pre-exposure prophylaxis could slash HIV infections in our most vulnerable communities
Seattle, Tuesday 24 February 2015: The European AIDS Treatment Group (EATG), Europe’s network of HIV activists and AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV, LGBT civil society...

Civil society call to the EU trio Presidencies to follow up on discussed ministerial declaration on HIV and co-infection in Europe and Central Asia

On 16 February, the EU HIV Civil Society Forum wrote to the trio EU Presidency to follow up on the conclusions of the EU Italian High Level Presidency recommending further work on a ministerial Declaration on HIV/AIDS and co-infections in Europe and Central Asia .
Brussels, 16 February 2015
We are writing on behalf of the EU HIV Civil Society Forum on HIV to follow up on the...

Report from November 2014 EU HIV Civil Society Forum and presentations published

The EU HIV Civil Society Forum on HIV has just published the report and supporting documents of its November 2014 meeting.
The meeting addressed the following items: the EU Presidency ministerial conference on HIV and declaration; the ECDC report of progress made on the last ten years and challenges ahead; the continued need for a new policy framework on HIV, TB, Hepatitis C and STIs...

Report meeting of EU Commissioner for Health and Food Safety Vytenis Andriukaitis and the Civil Society Forum on HIV/AIDS

Report meeting of EU Commissioner for Health and Food Safety Vytenis Andriukaitis and the Civil Society Forum on HIV/AIDS
Rome, 27 November 2014
EU Health and Food Safety Commissioner Vytenis Andriukaitis met the representatives of the Civil Society Forum on HIV/AIDS (CSF) during the “Fighting against HIV/AIDS ten years after the Dublin Declaration:...

Civil Society calls for active and responsible political leadership in Europe to curb the HIV epidemic

Press release
“We call on your leadership“
Rome 27th November 2014
Over 30 years into the epidemic, there is ample evidence of what works and what does not work in addressing HIV and yet, strikingly, the epidemic continues to grow in Europe. Civil society organisations are calling for renewed political leadership at European level that is based on...

The call for the next EUPATI Expert Patient Training Course, starting in Autumn 2015, is now open and will close on March 31.
Community representatives with experience in medicine R&D advocacy, with interest in increasing their knowledge and become part of a network of patient experts are invited to apply through the link below....

Swim for Life is a fundraising swim marathon organised yearly since 1996 by the non-profit organisation (a.s.b.l.) Brussels Gay Sports (BGS). The money raised is transferred in full to concrete AIDS help and prevention projects. More than 360,000 € have been raised to date.
This year one of the projects supported by Swim for Life is EATG's CoPE project .
The...

The latest updates of the activities of EATG members and staff at the EACS 14th AIDS Conference in Brussels. Reports, interviews, news - everything from the aspect of one of largest organisations for people living with HIV in Europe.

EATG returned from Kiev, Ukraine where the Youth in Positive Action training for East European and Central Asian communities of young people living with HIV/AIDS, their supporters and health care providers took place during the weekend of 19-21 July 2013.
20 young activists from Belarus, Ukraine, Russia, Uzbekistan, Kazakhstan, Kyrgyzstan and Romania came together...

Presenting the new and improved TBOnline.info – your source for TB news!

We are pleased to announce the completed renovation of TB Online – a website for activists, patients, healthcare workers, and researchers to learn more about tuberculosis (TB).
The website is maintained with the support of the European AIDS Treatment Group (EATG) and Treatment Action Group (TAG).
TB Online is the official site of the Global TB Community Advisory Board...

Europe needs the HIV prevention pill now
Pre-exposure prophylaxis could slash HIV infections in our most vulnerable communities
Seattle, Tuesday 24 February 2015: The European AIDS Treatment Group (EATG), Europe’s network of HIV activists and AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV, LGBT civil society...

Civil society call to the EU trio Presidencies to follow up on discussed ministerial declaration on HIV and co-infection in Europe and Central Asia

On 16 February, the EU HIV Civil Society Forum wrote to the trio EU Presidency to follow up on the conclusions of the EU Italian High Level Presidency recommending further work on a ministerial Declaration on HIV/AIDS and co-infections in Europe and Central Asia .
Brussels, 16 February 2015
We are writing on behalf of the EU HIV Civil Society Forum on HIV to follow up on the...

Report from November 2014 EU HIV Civil Society Forum and presentations published

The EU HIV Civil Society Forum on HIV has just published the report and supporting documents of its November 2014 meeting.
The meeting addressed the following items: the EU Presidency ministerial conference on HIV and declaration; the ECDC report of progress made on the last ten years and challenges ahead; the continued need for a new policy framework on HIV, TB, Hepatitis C and STIs...

The European AIDS Treatment Group and AVAC organized an unprecedented three-day workshop: New Developments in HIV Prevention . The EATG-AVAC collaboration is an attempt to update EATG members on the latest developments in biomedical HIV prevention approaches; facilitate the exchange of state-of-the-art information on HIV prevention research topics between researchers...

The seventh international workshop on viral hepatitis, held in Sitges, Barcelona, Spain - aka “Sitges VII” focused on access to treatment and care for people living with hepatitis C, whether living with hepatitis C alone or living with HIV co-infection. Community delegates and their allies met with representatives of pharmaceutical industry between Friday 3rd through Sunday 5th of...

The seventh international workshop on viral hepatitis, held in Sitges, Barcelona, Spain - aka “Sitges VII” focused on access to treatment and care for people living with hepatitis C, whether living with hepatitis C alone or living with HIV co-infection. Community delegates and their allies met with representatives of pharmaceutical industry between Friday 3 rd through...

The seventh international workshop on viral hepatitis, held in Sitges, Barcelona, Spain - aka “Sitges VII” focused on access to treatment and care for people living with hepatitis C, whether living with hepatitis C alone or living with HIV co-infection. Community delegates and their allies met with representatives of pharmaceutical industry between Friday 3 rd through...

The seventh international workshop on viral hepatitis, held in Sitges, Barcelona, Spain - aka “Sitges VII” focused on access to treatment and care for people living with hepatitis C, whether living with hepatitis C alone or living with HIV co-infection. Community delegates and their allies met with representatives of pharmaceutical industry between Friday 3 rd through...

EATG-GAT Portugal community brief on the impact of economic austerity on the HIV response

The paper provides a local community perspective on current challenges to the HIV response in Portugal and issues to be discussed with different actors. The working paper covers the following aspects:
The impact of economic austerity on the HIV response in Portugal: a community perspective.
1. Introduction....

The report of the TB ECAB of 2013 is now available online.
The purpose of the report, based on the TB ECAB meeting held in Brussels between May 17-19, is to inform ECAB and community advocates on HIV+TB treatment, care and research advocacy, in order to increase the capacity of the ECAB members and partners to get further involved in TB drugs, diagnostics development and access, and to...

EATG community brief on the impact of economic austerity on the HIV response in Spain

The paper provides a local community perspective on current challenges to the HIV response in Spain and issues to be addressed for discussion with different actors. The working paper covers the following aspects:
The Epidemiological Situation in Spain
Reporting
Key affected and vulnerable groups
Impact of economic austerity measures on the...

“Treating people with HCV who have been left behind”, otherwise known as Sitges VI which was held between 4-6 of October, 2013- Sitges, Spain.
The Sitges VI meeting was convened to further EATG advocacy goals in discussion with representatives from Abbvie, Bristol Meyers Squibb, Gilead Sciences, MSD and Janssen pharmaceutical companies, with input from patient/activists, allied...

The seventh international workshop on viral hepatitis, held in Sitges, Barcelona, Spain - aka “Sitges VII” focused on access to treatment and care for people living with hepatitis C, whether living with hepatitis C alone or living with HIV co-infection. Community delegates and their allies met with representatives of pharmaceutical industry between Friday 3rd through Sunday 5th of...

The seventh international workshop on viral hepatitis, held in Sitges, Barcelona, Spain - aka “Sitges VII” focused on access to treatment and care for people living with hepatitis C, whether living with hepatitis C alone or living with HIV co-infection. Community delegates and their allies met with representatives of pharmaceutical industry between Friday 3 rd through...

The seventh international workshop on viral hepatitis, held in Sitges, Barcelona, Spain - aka “Sitges VII” focused on access to treatment and care for people living with hepatitis C, whether living with hepatitis C alone or living with HIV co-infection. Community delegates and their allies met with representatives of pharmaceutical industry between Friday 3 rd through...

The seventh international workshop on viral hepatitis, held in Sitges, Barcelona, Spain - aka “Sitges VII” focused on access to treatment and care for people living with hepatitis C, whether living with hepatitis C alone or living with HIV co-infection. Community delegates and their allies met with representatives of pharmaceutical industry between Friday 3 rd through...

We are very pleased to announce that EATG has published “The Impatient Patient, from Anger to Activism”. The review presents the history, working models, relevance and perspectives of the European Community Advisory Board (ECAB). All those interested in the history and development of ECAB can download the document here

On November 5th The European AIDS Treatment Group (EATG) announced the launch of an audit designed to assess current and future levels of investment in research into a cure for HIV.
Over the last year there has been a renewed focus on the exciting possibility of a world free of AIDS. As Bill Clinton said at the recent International AIDS Conference held in Melbourne, Australia:
“The...

Hepatitis C: Sit in of European patients to request access to new medicines, on occasion of the informal meeting of European Health Ministers in Milan

September 22st, 2014
In support of the Call to EU Ministers of Health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding Universal Access to Curative Hepatitis C Treatment in the EU an beyond (attached), EPAC, Lila and Nadir with the support of the subscribers of the call, European Civil Society Forum on HIV/AIDS (CSF), European Aids Treatment Group (EATG), Aids Action Europe...

The members and staff from the European AIDS Treatment Group want to express their sincere condolences to the families and friends from the passengers from flight MH17 flying to Kuala Lumpur. Some people on board this flight were travelling to the 20th International AIDS Conference taking place in Melbourne. EATG wants to send its support to the colleagues, friends and...

Expanded access, compassionate use programmes & affordable pricing for Sovaldi & new HCV drugs: urgently needed by people living with hepatitis C

Official European AIDS Treatment Group (EATG) Press Statement released at the European Community Advisory Board Thematic Hepatitis C Meeting: Lisbon, Portugal
Pharmaceutical companies must provide access to their game-changing oral hepatitis C drugs to people with hepatitis C virus (HCV) who need them most, through life-saving expanded access and compassionate use...